TriangleNCT02301039 · OUTCOME
The Progression-free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- up to 5 yrs
What was measured
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Groups in this outcome
Soft Tissue Sarcoma
Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab was administered at 200 mg intravenously every 3 weeks Pembrolizumab
Bone Sarcoma
Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \[de-differentiated or mesenchymal\]. Pembrolizumab was administered at 200 mg intravenously every 3 weeks Pembrolizumab
Expansion Cohort
Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
| Group | Source count |
|---|---|
| Soft Tissue Sarcoma | 37 |
| Bone Sarcoma | 39 |
| Expansion Cohort | 53 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Soft Tissue Sarcoma | 18 | Not reported | 8 | 22 | Not reported |
| Bone Sarcoma | 8 | Not reported | 7 | 9 | Not reported |
| Expansion Cohort | 8 | Not reported | 7 | 13 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 8
- upper Limit
- 22
- value
- 18
- group Id
- OG001
- lower Limit
- 7
- upper Limit
- 9
- value
- 8
- group Id
- OG002
- lower Limit
- 7
- upper Limit
- 13
- value
- 8
- denoms
- counts
- group Id
- OG000
- value
- 37
- group Id
- OG001
- value
- 39
- group Id
- OG002
- value
- 53
- units
- Participants
- description
- The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab was administered at 200 mg intravenously every 3 weeks Pembrolizumab
- id
- OG000
- title
- Soft Tissue Sarcoma
- description
- Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \[de-differentiated or mesenchymal\]. Pembrolizumab was administered at 200 mg intravenously every 3 weeks Pembrolizumab
- id
- OG001
- title
- Bone Sarcoma
- description
- Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
- id
- OG002
- title
- Expansion Cohort
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- up to 5 yrs
- title
- The Progression-free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice